Universal Screening for Vocal Fold Motion Impairment in Children Undergoing Congenital Cardiac Surgery

Overview

The purpose of this study is to determine how often heart or chest surgery in children leads to problems with the movement of the vocal folds.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 13, 2020

Detailed Description

Pediatric vocal fold motion impairment (VFMI) is a well-known cause of dysphonia and dysphagia. Previous studies have demonstrated the most common etiology for pediatric VFMI is cardiothoracic surgery which is possibly due to a variety of mechanisms.The investigators hypothesize that universal screening of neonates for VMFI following congenital cardiac surgery (CCS) will lead to a more accurate incidence and earlier diagnosis of VFMI. They believe that earlier identification will lead to changes in feeding regimens that may decrease length of stay (LOS), decrease time to oral feeding, earlier otolaryngologic intervention if indicated, and decreased rates of readmission for pulmonary or feeding complications. The investigators will also use this information to design a refined algorithm for targeted screening of patients who are more likely to have VFMI based on patient and surgery characteristics.

Interventions

  • Procedure: Flexible fiberoptic laryngoscopy
    • Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
  • Procedure: Laryngeal ultrasonography
    • Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.

Arms, Groups and Cohorts

  • No Intervention: Neonates with congenital cardiac disease (retrospective)
    • Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
  • Active Comparator: Neonates with congenital cardiac disease (prospective)
    • Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.

Clinical Trial Outcome Measures

Primary Measures

  • Postoperative length of stay (retrospective)
    • Time Frame: Baseline
    • The number of days of postoperative stay in the hospital will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.
  • Number of readmissions related to feeding difficulty (retrospective)
    • Time Frame: Baseline
    • The number of readmissions to the hospital for feeding difficulties will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.
  • Number of readmissions related to aspiration (retrospective)
    • Time Frame: Baseline
    • The number of readmissions to the hospital for aspiration will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.
  • Time to initiation of feeding therapy (retrospective)
    • Time Frame: Baseline
    • The average time (in days) to start feeding therapy will be compiled by reviewing the medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016.
  • Number of participants with vocal fold motion impairment (prospective)
    • Time Frame: Baseline
    • The number of study participants diagnosed with VFMI following CCS universal screening will be recorded.
  • Postoperative length of stay (prospective)
    • Time Frame: Up to 180 days
    • The number of days of postoperative stay at the hospital will be recorded.
  • Time to initiation of feeding therapy (prospective)
    • Time Frame: Day 7
    • The number of days to start feeding therapy will be recorded.
  • Number of readmissions related to aspiration (prospective)
    • Time Frame: 3 months, 6 months, 12 months
    • The number of readmissions to the hospital for aspiration will be recorded.
  • Number of readmissions related to feeding difficulty (prospective)
    • Time Frame: 3 months, 6 months, 12 months
    • The number of readmissions to the hospital for feeding difficulties will be recorded.

Participating in This Clinical Trial

Inclusion Criteria

  • Children 18 and younger with congenital cardiac disease necessitating surgery – Children 18 and younger whose parents have given and signed an informed consent and HIPAA Authorization as well as the assent of the patient Exclusion Criteria:

  • History of prior cardiac surgery – Known history of VFMI prior to evaluation – Children 18 and younger who do not survive the immediate postoperative course will be excluded. – Further exclusion may be determined at the discretion of the Principal Investigator.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Emory University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nikhila Raol, Assistant Professor – Emory University
  • Overall Official(s)
    • Nikhila Raol, MD, MPH, Principal Investigator, Emory University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.